Navigation Links
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
Date:3/4/2013

hase 3 clinical trials and a New Drug Application submission is planned for the third quarter of 2013. AcelRx recently completed enrollment in a Phase 2 study for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command, and top-line results are expected in the second quarter of 2013.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the release of sufentanil NanoTab PCA System top-line clinical trial data, the release and anticipated timing of additional NanoTab System clinical trial data, the potential submission of an NDA for NanoTab System and the timing thereof, therapeutic and commercial potential of NanoTab System and the anticipated timing and therapeutic and commercial potential of other AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the ability of AcelRx Pharmaceuticals to successfully complete the clinical trials for the sufentanil NanoTab System, that fact that subsequent analyses of the top-line data may lead to different (including less favorable) interpretations of t
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. AcelRx Pharmaceuticals Provides Clinical Trial Updates
3. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
4. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
6. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
10. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
11. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... 2013  PENTAX Medical, a healthcare industry leader ... leader in ultrasound imaging, recently announced renewed collaborative ... further innovation in the development of Endoscopic Ultrasound ... and PENTAX Medical endoscopic portfolio have formed one ... systems. This agreement will continue to grow their ...
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... Healthcare Products Association (CHPA) today applauded the Alabama ... bill that significantly improves Alabama,s methamphetamine enforcement laws ... for meth-related crime and enhancements to the state,s ... called the National Precursor Log Exchange (NPLEx), successfully ...
... Colo., April 20, 2012  Results from the combined ... presented today at the 3rd European Lung Cancer ... was performed on serum samples from advanced non-squamous ... the combination therapy bevacizumab plus erlotinib.  Results showed ...
Cached Medicine Technology:CHPA Applauds Alabama Senate's Passage of Anti-Meth Bill 2VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 2VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 3
(Date:5/17/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) ... brain may make the call on which ear you ... The dominant side of your brain is where your ... human population is left-brain dominant, and those people tend ... who are right-brain dominant. In this study, scientists found ...
(Date:5/17/2013)... 17, 2013 Fighting addiction is hard ... for diabetics, treatment is more difficult and complicated. Drug ... to monitor blood sugar levels and administer insulin when ... drug rehab for diabetics needs to have ... needs of the diabetic, and has experience caring for ...
(Date:5/17/2013)... 17 (HealthDay News) -- Teen bullies are more likely ... finds. UT Dallas researchers analyzed several decades of ... All of them had similar working-class backgrounds and most ... were in their mid-50s. Nearly half of the ... years engaged in some form of criminal activity -- ...
(Date:5/17/2013)... SportsFanPlayground.com is currently offering a new ... $319.99, nearly 20% off of the retail price. , The ... Adventures and Carnival Games, and a complementary 3-month Xbox Live ... Kinect Star Wars Bundle available for shipping. The Star Wars bundle ... 360 console, a custom white Kinect sensor, an Xbox 360 wired ...
(Date:5/17/2013)... Guide to the DSM-5 explores all revisions to ... Manual, and shows clinicians how they can best ... most contentious resource. Written by a celebrated professor ... and new research to point out where DSM-5 ... the jury,s still out. Along the way, The ...
Breaking Medicine News(10 mins):Health News:Cellphone Use May Reveal Your 'Dominant Brain' 2Health News:Cellphone Use May Reveal Your 'Dominant Brain' 3Health News:Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics 2Health News:Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics 3Health News:Xbox 360 Kinect Bundle 20% Off at SportsFanPlayground.com 2
... are banned for manufacture, import and use in India. ... use in the country but their manufacture is allowed ... to Information (RTI) Act. ,As India grapples ... productivity and environmental safety, the government has also acknowledged ...
... Manipur are literally holding the state to ransom with ... huge extortion notices slapped by rebels. ,Pharmacies ... until Sunday after a rebel group demanded Rs.10 million ... Association and the All Manipur Pharmaceutical and Druggists Association. ...
... poison that can kill, arsenic also can prolong the lives ... new study out Saturday found. ,"This study shows ... earlier in the course of treatment," said Dr. Bayard Powell, ... and the lead author of the research delivered at the ...
... The last two decades have seen modest overall improvements in ... However, according to researchers at The University of Texas M. ... the rates for black women; differences in life expectancy between ... study, presented today (June 3) at the 43rd annual American ...
... the journal Health Psychology, by the American Psychological Association ... or mean disposition tend to have compromised lung ... were ruled out as possible causes of lung dysfunction. ... White 18-30 year olds from four metropolitan areas (sampled ...
... new study co-led by an urologist and a radiation ... specialty of the physician patients see can influence ... analyzed men with localized prostate cancer. It found that ... urologist are more likely to undergo surgery to remove ...
Cached Medicine News:Health News:25 Pesticides Banned in India, Others Face Partial Curbs 2Health News:Manipur Pharmacies Shut Down Fearing Separatist Threats 2Health News:Advanced Breast Cancer: Study Reveals White and Black Women Have Different Survival Rates 2Health News:Unhealthy Lungs Linked to Hostility? 2Health News:Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received 2Health News:Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received 3
Patient-Centered Therapy that promotes natural cardiac function....
... The Alliance Catheter Delivery ... manipulation, and stabilization of the ... Alliance CDS has a patented ... for quick and easy access ...
... throughout the world are facing difficult times ... of the blood supply in the face ... donor base. Clearly, these centers must find ... manage their existing donor pools, and to ...
The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
Medicine Products: